^
    Apply
    A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004) (NCT06345729)
    Phase 3
    Merck Sharp & Dohme LLC
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    05/24/2024
    Primary completion :
    02/19/2029
    Completion :
    02/18/2031
    KRAS
    |
    Keytruda (pembrolizumab) • MK-1084
    A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001) (NCT05067283)
    Phase 1
    Merck Sharp & Dohme LLC
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    12/17/2021
    Primary completion :
    08/19/2027
    Completion :
    08/19/2027
    PD-L1 • KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • carboplatin • 5-fluorouracil • pemetrexed • oxaliplatin • leucovorin calcium • MK-1084